Valuation: Black Diamond Therapeutics, Inc.

Market Cap 105M 94.33M 87.21M 78.99M 148M 10.01B 149M 1.04B 415M 5.24B 395M 386M 16.63B P/E 2026 *
-2.97x
P/E 2027 * -1.92x
Enterprise Value 105M 94.33M 87.21M 78.99M 148M 10.01B 149M 1.04B 415M 5.24B 395M 386M 16.63B EV / Sales 2026 *
16.8x
EV / Sales 2027 * -
Free-Float
99.34%
Yield 2026 *
-
Yield 2027 * -
1 day+4.57%
1 week-12.02%
Current month-2.92%
3 months+3.98%
6 months-32.22%
Current year-24.69%
1 week 1.64
Extreme 1.645
2.05
1 month 1.6
Extreme 1.6
2.14
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
8.71
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 A Free

Director

7,707 0.0134%
9/18/26 A Free

Director

6,801 0.0118%
9/18/26 A
NEA Management Co. LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
+4.57%-12.02%-52.96%+3.39% 105M
+0.65%-3.36%+36.98%+60.50% 64.14B
+1.23%+2.73%+12.31%+84.00% 55.53B
+1.17%+1.31%+12.52%+104.30% 53.03B
+2.76%+0.87%+27.92%+55.07% 45.99B
+2.00%-3.39%+17.83%+119.04% 42.45B
+1.34%-2.86%+224.43%+914.08% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
-2.55%+41.97%+102.69%+89.25% 34.47B
-2.72%-0.44%+23.18%-10.77% 24.23B
Average +0.88%+2.47%+41.61%+146.44% 39.26B
Weighted average by Cap. +0.74%+3.48%+49.14%+160.25%

Financials

2026 *2027 *
Net sales 6.25M 5.61M 5.18M 4.7M 8.77M 595M 8.88M 61.99M 24.69M 311M 23.45M 22.96M 989M -
Net income -36.96M -33.16M -30.66M -27.77M -51.88M -3.52B -52.51M -367M -146M -1.84B -139M -136M -5.85B -64.65M -58M -53.63M -48.57M -90.74M -6.16B -91.83M -641M -255M -3.22B -243M -237M -10.23B
Net Debt - -
Projected Income Statement - Annual - Black Diamond Therapeutics, Inc.
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
28/10/26 $1.830 +4.57% 1,043,445
27/10/26 $1.750 +3.55% 1,099,330
26/10/26 $1.690 -10.11% 862,916
23/10/26 $1.880 -9.62% 927,809
22/10/26 $2.080 0.00% 790,955
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Black Diamond Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.830USD
Average target price
10.00USD
Spread / Average Target
+446.45%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Black Diamond Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. BDTX Stock